This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ultrasound Breast Cancer Imaging Device Created At The Karmanos Cancer Institute One Step Closer To FDA Approval

DETROIT, Jan. 28, 2013 /PRNewswire-USNewswire/ -- SoftVue, the whole breast ultrasound imaging device created by two scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for market clearance. It's anticipated that this first application clearance could come this spring, with several other FDA submissions to follow over the next couple of years. This promising imaging tool has the potential to aid in detecting breast cancer earlier, especially in women with dense breasts.

(Logo:  http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO)

Peter Littrup, M.D., and Neb Duric, Ph.D., of the Karmanos Cancer Institute and Wayne State University School of Medicine, and their team have been working to perfect the SoftVue technology for more than a decade. The Karmanos Cancer Institute spun off a company in 2009 called Delphinus Medical Technologies to help secure funding to bring this device closer to commercialization. Since then, Delphinus has grown to 19 employees, many of whom are engineers, and plans are underway to gradually increase the sales staff once the first FDA market clearance is obtained.

"We are pleased to see the progress of SoftVue over the past 12 years, first with the concept followed by the prototype created at Karmanos a few years later," said Gerold Bepler, M.D., Ph.D., president and CEO of the Barbara Ann Karmanos Cancer Institute. "After years of dedication and hard work by co-creators Peter Littrup, M.D., and Neb Duric, Ph.D., along with their team, we are delighted that Karmanos has the first commercial-grade SoftVue system to offer to our patients. Information obtained from this new SoftVue system will continue the next round of clinical research for use in diagnostic breast imaging.

"SoftVue is another example of the exceptional cancer research and innovative technology created right here at the Karmanos Cancer Institute in Detroit, and built in Michigan."   

More than $32 million in funding, including venture capital and other grants, helped turn SoftVue's technology into a commercial product – pending FDA clearance to market. The first round of venture capital funding included Michigan companies Arboretum Ventures, Altarum Institute, Beringea, LLC's InvestMichigan! Growth Capital Fund and North Coast Technology Investors. Other funding, past and present, was received from several private donors along with grants from the National Institutes of Health, the Susan G. Komen Breast Cancer Foundation and the Michigan Economic Development Corp. Currently, the Karmanos Cancer Institute has the only commercial-grade SoftVue system in the world. 

How SoftVue Works

SoftVue uses ultrasound waves, rather than X-rays, which have the potential to aid in detecting early stages of breast cancer, even in women with dense breast tissue often not picked up by mammography.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,390.52 +195.10 1.13%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs